Dr. Gadek focuses on the Sonic Hedgehog (Shh) signaling pathway, which can be altered in rhabdomyosarcoma (RMS) patients. RMS is the most common soft-tissue sarcoma in children, but survival rates and treatments for high-risk patients have not improved in three decades. Dr. Gadek will examine the timing of tumor development and the role of Shh signaling in tumor location and formation. This may lead to diagnostic markers and tools for identifying high-risk patients with altered Sonic Hedgehog signaling, which could improve treatment options and outcomes.
Head and Neck Cancer
Current Projects

Head and neck cancers usually begin in the squamous cells that line the mucosal surfaces inside the mouth, nose and throat. Even with aggressive treatment including surgery, radiation therapy and chemotherapy, these tumors often recur with poor prognosis. Dr. Mowery will use patient samples and mouse models to investigate why these cancers are resistant to radiation treatment and to test new therapeutic approaches to improve outcomes for patients. She will also conduct a Phase 1 clinical trial to evaluate the effectiveness of using a combination of a radiation sensitizer (a drug that makes cancer cells more vulnerable to radiation therapy), radiation therapy and immunotherapy to treat patients with recurrent head and neck cancer.